References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [ Internet]. 2018;68:394–424. cited 2019 Dec 5]. Available from: http://doi.wiley.com/10.3322/caac.21492
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin [ Internet]. 2020. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31912902
- Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet [ Internet]. 2019;393:1240–1253.
- Matulonis UA, Sood AK, Fallowfield L, et al. Ovarian cancer. Nat Rev Dis Primers [ Internet]. 2016;2:1–22. [cited 2020 Feb 9]. Available from: www.nature.com/nrdp
- Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov [ Internet]. 2015;5:1137–1154. [cited 2019 Apr 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26463832
- Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615.
- Prat J, D’Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol [ Internet]. 2018;80:11–27.
- Howlader N, Noone AM, Krapcho M, et al., eds. SEER cancer statistics review, 1975-2016, National Cancer Institute. Bethesda, MD, based on november 2018 SEER data submission, posted to the SEER web site, April 2019. [ Internet]. 2019. Available from: https://seer.cancer.gov/csr/1975_2016/
- Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284–296.
- Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2:482–490.
- Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A [ Internet]. 2011;108:18032–18037. [cited 2019 Jul 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22006311
- Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group. J Clin Oncol. 2012;30:2654–2663.
- Randall LM, Pothuri B, Swisher EM, et al. Society position statements/white papers multi-disciplinary summit on genetics services for women with gynecologic cancers: a society of gynecologic oncology white paper. 2017 [cited 2020 Jan 27]. Available from: http://dx.doi.10.1016/j.ygyno.2017.06.002.
- Society of gynecologic oncology: position statement, genetic testing for ovarian cancer [Internet]. 2014 [cited 2020 Jan 27]. Available from: https://www.sgo.org/clinical-practice/guidelines/genetic-testing-for-ovarian-cancer/.
- Hampel H, Bennett RL, Buchanan A, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17:70–87.
- Pilarski R, Berry MP, Jude S, et al. NCCN guidelines version 1.2020 Genetic/familial high-risk assessment: breast, ovarian, and pancreatic. 2020.
- HUNN J, RODRIGUEZ GC. NCCN clinical practice guidelines in oncology - ovarian cancer including fallopian tube cancer and primary peritoneal cancer v1.2019. NCCN. 2019;
- Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol [ Internet]. 2020;38. [cited 2020 Feb 9]
- D’Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst) [ Internet]. 2018;71:172–176.
- Howlader N, Noone A, Krapcho M, et al. National cancer institute SEER cancer statistics review 1975-2012. Natl Cancer Inst [ Internet]. 2015;103:1975–2012. Available from: http://seer.cancer.gov/csr/1975_2012/.
- Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial. Lancet Oncol [ Internet]. 2013;14:1020–1026. [cited 2020 Jan 28]: www.thelancet.com/oncology
- Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019;394:2084–2095.
- Kyrgiou M, Salanti G, Pavlidis N, et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst [ Internet]. 2006;98:1655–1663. [cited 2019 Dec 6]. Available from: http://jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/
- Chan JK, Brady MF, Penson RT, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016;374:738–748.
- Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med [ Internet. 2011;365:2473–2483. [cited 2019 Dec 6]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1104390
- Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol [Internet]. 2019;37:2317–2328. [cited 2019 Dec 6]
- Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928–936.
- Gunderson CC, Matulonis U, Moore KN. Management of the toxicities of common targeted therapeutics for gynecologic cancers. 2018 [cited 2020 Jan 28]. DOI:10.1016/j.ygyno.2018.01.010.
- Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med [Internet]. 2006;354:34–43. [cited 2019 Dec 6]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa052985
- Walker JL, Brady MF, Wenzel L, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology/gynecologic oncology group study [Internet]. J Clin Oncol. 2019;37:1380–1390.
- Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230–240.
- González-Martín A, Sánchez-Lorenzo L, Bratos R, et al. First-line and maintenance therapy for ovarian cancer: current status and future directions. Drugs. 2014;74(8):879–889.
- Tsibulak I, Zeimet AG, Marth C, Hopes and failures in front-line ovarian cancer therapy. Crit Rev Oncol Hematol [Internet]. 2019;143: 14–19. [cited 2020 Feb 10]. Available from: https://doi.org/10.1016/j.critrevonc.2019.08.002
- Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin methods and materials criteria for patient selection. J Clin Oncol. 1991;9:389–393.
- Mcgee J, Bookman M, Harter P, et al. Fifth ovarian cancer consensus conference: individualized therapy and patient factors.
- Coleman RL, Spirtos NM, Enserro D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med [Internet]. 2019;381:1929–1939. [cited 2019 Dec 6]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1902626
- Bois AD, Sehouli J, Vergote I, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III/ENGOT-ov20. J Clin Oncol. 2020;38;suppl;abstr 6000.
- Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–2106.
- Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol [Internet]. 2010;28:3323–3329. [cited 2019 Dec 6]. Available from: www.jco.org
- Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107:588–591.
- Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol [Internet]. 2006;24:4699–4707. [cited 2019 Dec 6]. Available from: www.jco.org
- Joly F, Ray-Coquard I, Fabbro M, et al. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial ☆. 2011;
- Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–2045.
- Aghajanian C, Goff B, Nycum LR, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139:10–16.
- Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779–791.
- Pfisterer J, Shannon CM, Baumann K, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol [Internet]. 2020;21:699–709. [cited 2020 May 17]. Available from: www.thelancet.com/oncology
- Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol [Internet]. 2004;22:3120–3125. [cited 2019 Dec 6]. Available from: www.jco.org
- Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23:2605–2612.
- Stuart GCE, Kitchener H, Bacon M, et al. Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer. 2010;2011(21):750–755.
- Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21:771–775.
- Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol [Internet]. 2001;19:3312–3322. [cited 2019 Mar 30]. Available from: http://ascopubs.org/doi/10.1200/JCO.2001.19.14.3312
- Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. [cited 2019 Dec 6]. Available from: www.elsevier.com/locate/ygyno.
- Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. 2007 [cited 2019 Dec 6]. Available from: www.jco.org.
- Poveda AM, Selle F, Hilpert F, et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III aurelia trial [Internet]. J Clin Oncol. 2015;3836–3838. cited 2020 Jan 29. Available from: www.jco.org
- Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. 2007 [cited 2019 Dec 6]. Available from: www.jco.org.
- Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302–1308.
- Matulonis UA, Pereira L, Liu J, et al. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. 2012;
- Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol [Internet]. 2007;25:5180–5186. [cited 2020 Feb 10]. Available from: www.jco.org
- Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. [Internet]. 2008;26:76–82. Available from: https://pubmed.ncbi.nlm.nih.gov/18165643.
- Miller D, Nevadunsky N, Palliative care and symptom management for women with advanced ovarian cancer. Hematol Oncol Clin North Am [Internet]. 2018;32: 1087–1102. [cited 2020 Feb 10].
- Walsh D, Davis M, Ripamonti C, et al. 2016 Updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer. 2017;25:333–340.
- Mouw KW, D’Andrea AD. Crosstalk between the nucleotide excision repair and Fanconi anemia/BRCA pathways. DNA Repair (Amst). 2014;19:130–134.
- Hennessy BTJ, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28:3570–3576.
- Lynn Baldwin R, Nemeth E, Tran H, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study 1. Cancer Res. 2000;60(19): 5329–5333.
- Esteller M. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst [Internet]. 2000;92:564–569. [cited 2019 Dec 12]. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/92.7.564
- Murai J, Huang SYN, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res [Internet]. 2012;72:5588–5599. [cited 2020 Jan 29]: http://cancerres.aacrjournals.org/
- Shen Y, Aoyagi-Scharber M, Wang B. Trapping poly(ADP-Ribose) polymerase. J Pharmacol Exp Ther Am Soc Pharmacol Exp Ther. 2015;353(3)446–457.
- Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol [Internet]. 2017;18:610–621. [cited 2020 Feb 20]. Available from: www.nature.com/nrm
- Maya-Mendoza A, Moudry P, Merchut-Maya JM, et al. High speed of fork progression induces DNA replication stress and genomic instability. Nature [Internet]. 2018. [cited 2020 May 5]. DOI:10.1038/s41586-018-0261-5.
- Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol [Internet]. 2010;28:2512–2519. [cited 2020 May 5]. Available from: www.jco.org
- Mukhopadhyay A, Elattar A, Cerbinskaite A, et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res. 2010;16:2344–2351.
- Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol [Internet]. 2011;12:852–861.
- Ceccaldi R, O’connor KW, Mouw KW, et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. 2015 [cited 2020 Feb 10]. Available from: http://cancerres.aacrjournals.org/.
- Damia G, Broggini M Platinum resistance in ovarian cancer: role of DNA repair. Cancers (Basel).MDPI AG; 2019.
- LaFargue CJ, Molin GZD, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol [Internet]. 2019;20:e15–e28. [cited 2020 May 11]. Available from: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30786-1/fulltext#.XrmoCT-6zUs.mendeley
- González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391–2402.
- Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. [Internet]. 2019;20:636–648. [cited 2020 Jan 15]. Available from: www.thelancet.com/oncology
- Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2017;72:91–92.
- Berek JS, Matulonis UA, Peen U, et al. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018;29:1784–1792.
- Niraparib FDA FDA label [Internet]. 2019 [cited 2020 May 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf.
- Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med [Internet]. 2018;379:2495–2505. [cited 2019 Dec 17]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1810858
- Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–1284.
- Olaparib FDA access [Internet]. [cited 2019 Dec 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf.
- Oza AM, Tinker AV, Oaknin A, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147:267–275.
- Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–1961.
- Murai J, Huang SYN, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13:433–443.
- U.S. Food & Drug Administration. FDA approved olaparib (LYNPARZA) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [Internet]. 2018 [cited 2019 Dec 17]. Available from: https://www.fda.gov/drugs/fda-approved-olaparib-lynparza-astrazeneca-pharmaceuticals-lp-maintenance-treatment-adult-patients.
- FDA approves niraparib for first-line maintenance of advanced ovarian cancer | FDA [Internet]. [ cited 2020 May 5]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer.
- Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med [Internet]. 2019;381:2416–2428. [cited 2020 Jan 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31851799
- FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers | FDA [Internet]. [cited 2020 May 11]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary.
- Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25): 2403–2415
- Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol [Internet]. 2015;33:244–250. [cited 2019 Dec 27]. Available from: www.jco.org
- Vanderstichele A, Van Nieuwenhuysen E, Han S, et al. Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. J Clin Oncol. 2019;37:5507.
- Penson RT, Villalobos VR, Cibula D, et al. Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): phase III SOLO3 trial. J Clin Oncol [Internet]. 2019;37:5506.
- Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol [Internet]. 2012;30:372–379. [cited 2020 May 5]. Available from: www.jco.org
- Balasubramaniam S, Beaver JA, Horton S, et al. FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation–associated advanced ovarian cancer. Clin Cancer Res Am Assoc Cancer Res Inc. 2017;23(23):7165–7170.
- Kristeleit R, Shapiro GI, Burris HA, et al. A phase I–II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017;23:4095–4106.
- Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18:75–87.
- FDA approves niraparib for HRD-positive advanced ovarian cancer | FDA [Internet]. [cited 2019 Dec 17]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer.
- Moore KN, QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of.. | oncologyPRO. Ann Oncol [Internet]. 2018;29: viii332–viii358. [cited 2020 Feb 11]
- Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer. N Engl J Med. 2012;69:594–596.
- Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol [Internet]. 2014;15:852–861. [cited 2019 Dec 22]: www.thelancet.com/oncology
- Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. NEJM [Internet]. 2017;72:91–92. [cited 2019 Apr 9]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1611310
- Ison G, Howie LJ, Amiri-Kordestani L, et al. FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy. Clin Cancer Res. 2018;24:4066–4071.
- Poveda A, Floquet A, Ledermann JA, et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Oncol. 2020;38.
- Veneris JT, Matulonis UA, Liu JF, et al. Choosing wisely: selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations [Internet]. Gynecol Oncol. 2019. [cited 2019 Dec 2]. DOI:10.1016/j.ygyno.2019.09.021.
- Lim J, Yang K, Taylor-Harding B, et al. VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. Neoplasia (United States). 2014;16:343–353.e2.
- Kaplan AR, Gueble SE, Liu Y, et al. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. Sci Transl Med. 2019;11(492):eaav4508.
- Bindra RS, Gibson SL, Meng A, et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res. 2005;65:11597–11604.
- Bindra RS, Schaffer PJ, Meng A, et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol. 2004;24:8504–8518.
- Chan N, Pires IM, Bencokova Z, et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res. 2010;70:8045–8054.
- Dean E, Middleton MR, Pwint T, et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer [Internet]. 2012;106:468–474. [cited 2020 Feb 11]: http://www.nature.com/articles/bjc2011555
- Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study. Lancet Oncol. 2014;15:1207–1214.
- Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019;30:551–557.
- Mirza MR, Åvall Lundqvist E, Birrer MJ, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol [Internet]. 2019;20:1409–1419. [cited 2019 Dec 24]. Available from: www.thelancet.com/oncology
- Lheureux S, Oaknin A, Garg S, et al. Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A princess margaret consortium – GCIG Phase II trial. J Clin Oncol [Internet]. 2019;37:5521. [cited 2019 Dec 29] Available from: http://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.5521
- Disis ML, Taylor MH, Kelly K, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer. JAMA Oncol [Internet]. 2019;5:393. [cited 2019 Apr 1].
- Matulonis UA, Shapira-Frommer R, Santin A, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase 2 KEYNOTE-100 study. J Clin Oncol [Internet]. 2018;36:5511. [cited 2019 Apr 1]. Available from: http://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.5511
- Ding L, Kim HJ, Wang Q, et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep [Internet]. 2018;25:2972–2980.e5. [cited 2019 Apr 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30540933
- Shen J, Zhao W, Ju Z, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res [Internet]. 2019;79:311–319. [cited 2019 Apr 1]. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-18-1003
- Drew Y, de Jonge M, Hong SH, et al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA -mutated (gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC). Gynecol Oncol [Internet]. 2018;149:246–247. [cited 2019 Apr 1]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0090825818308333
- Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol [Internet]. 2019. [cited 2019 Jun 25]. Available from: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2019.1048.
- Haynes B, Murai J, Lee JM. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treat Rev. 2018;71:1–7.
- O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell [Internet]. 2015;60:547–560. [cited 2020 Feb 11]. https://linkinghub.elsevier.com/retrieve/pii/S109727651500831X
- Kantidze OL, Velichko AK, Luzhin AV, et al. Synthetically lethal interactions of ATM, ATR, and DNA-PKcs. Trends Cancer [Internet]. 2018;4:755–768.
- Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell [Internet]. 2017;66:801–817.
- Flynn RL, Zou L. ATR: a master conductor of cellular responses to DNA replication stress. Trends Biochem Sci [Internet]. 2011;36:133–140. [cited 2019 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20947357
- Yazinski SA, Comaills V, Buisson R, et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 2017;31:318–332.
- Schoonen PM, Kok YP, Wierenga E, et al. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells. Mol Oncol. 2019;13:2422–2440.
- Kim H, George E, Ragland RL, et al. Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin Cancer Res. 2017;23:3097–3108.
- Brill E, Yokoyama T, Nair J, et al. Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer. Oncotarget. 2017;8:111026–111040.
- Parmar K, Kochupurakkal BS, Lazaro JB, et al. The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition. Clin Cancer Res. 2019;25:6127–6140.
- Krajewska M, Heijink AM, Bisselink YJWM, et al. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene [Internet]. 2012;32:3001–3008. [Cited Jul 16]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22797065
- Garcia TB, Snedeker JC, Baturin D, et al. A small-molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia. Mol Cancer Ther. 2017;16:2058–2068.
- Lallo A, Frese KK, Morrow CJ, et al. The combination of the PARP inhibitor olaparib and the WEE1 Inhibitor AZD1775 as a new therapeutic option for small cell lung cancer. Clin Cancer Res. 2018;24:5153–5164.
- Juvekar A, Hu H, Yadegarynia S, et al. Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion. Proc Natl Acad Sci U S A [Internet]. 2016;113:E4338–E4347. [cited 2019 Jul 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27402769
- Ibrahim YH, García-García C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov [Internet]. 2012;2:1036–1047. [cited 2019 Jul 23]: Available from: http://www.ncbi.nlm.nih.gov/pubmed/22915752
- Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov [Internet]. 2012;2:1048–1063. [cited 2019 Jul 23]: http://www.ncbi.nlm.nih.gov/pubmed/22915751
- Rehman FL, Lord CJ, Ashworth A. The promise of combining inhibition of PI3K and PARP as cancer therapy. Cancer Discov [Internet]. 2012;2:982–984. [cited 2019 Jul 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23148373
- Matulonis UA, Wulf GM, Barry WT, et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol [Internet]. 2017;28:512–518. [cited 2019 Jul 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27993796
- Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol [Internet]. 2019;20:570–580.
- Mukhopadhyay A, Drew Y, Matheson E, et al. Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors. Biochem Pharmacol [Internet]. 2018;1. Available from: https://doi.org/10.1016/j.bcp.2018.10.011
- FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma | FDA [Internet]. [ cited 2020 Feb 11]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-gbrcam-metastatic-pancreatic-adenocarcinoma.
- Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med [Internet]. 2019;381:317–327. [cited 2020 Feb 11]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1903387
- FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer | FDA [Internet]. [cited 2020 Feb 11]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-gbrcam-her2-negative-locally-advanced-or-metastatic-breast-cancer.
- FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer | FDA [Internet]. [cited 2020 May 20]. Available from: https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate.
- FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer | FDA [Internet]. [cited 2020 May 20]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer
- Shenolikar R, Durden E, Meyer N, et al. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States. 2018 [cited 2020 Jan 14]. Available from: https://doi.org/10.1016/j.ygyno.2018.09.003.
- Sella T, Stone RM, The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: understanding the baseline incidence. Gynecol Oncol [Internet]. 2018;151: 187–189. [cited 2020 Jan 14]
- Childers CP, Childers KK, Maggard-Gibbons M, et al. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35:3800–3806.
- Hoskins PJ, Gotlieb WH, Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: a review of the literature. CA Cancer J Clin [Internet]. 2017cited 2020 Jan 14;67: 493–506.
- Pettitt SJ, Krastev DB, Brandsma I, et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat Commun [Internet]. 2018;9:1849. [cited 2019 Jul 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29748565
- Nacson J, Krais JJ, Bernhardy AJ, et al. BRCA1 mutation-specific responses to 53BP1 loss-induced homologous recombination and PARP inhibitor resistance. Cell Rep. 2018;24:3513–3527.e7.
- Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol Off J Eur Soc Med Oncol [Internet]]. 2018;29:1203–1210. [cited 2019 Jul 27]: Available from: http://www.ncbi.nlm.nih.gov/pubmed/29635390